The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback